Aclarion, Inc. (ACON) vs CNS Pharmaceuticals, Inc. (CNSP)

A side-by-side comparison of Aclarion, Inc. and CNS Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ACON

Aclarion, Inc.

$7M

$2.32HealthcareDelayed quote: Oct 6, 2026, 2:19 PM EDT

CNSP

CNS Pharmaceuticals, Inc.

$8M

$5.44HealthcareDelayed quote: Oct 6, 2026, 2:03 PM EDT

Total return — ACON vs CNSP

growth of $100 · dividends reinvested · last 4y

ACON -100.0% (-95.1%/yr)CNSP -100.0% (-93.5%/yr)CNSP compounded faster over this window

ACON CNSP

ACON vs CNSP: by the numbers

•CNSP is the larger company ($8M vs $7M market cap).
•Both run net losses; CNSP's is the smaller (0.00% vs -10978.48% net margin).

Metrics side by side

Valuation

Metric	ACON	CNSP
P/S ratio	79.66	N/A
P/B ratio	0.39	0.44

Profitability

Metric	ACON	CNSP
Gross margin	-291.27%	0.00%
Operating margin	-9312.55%	0.00%
Net margin	-10978.48%	0.00%
ROE	-54.09%	-91.75%
ROIC	-57.11%	-92.94%

Growth (annualized)

Metric	ACON	CNSP
Revenue CAGR (5Y)	3.75%	N/A
Total return CAGR (5Y)	N/A	-91.63%

Go deeper

Full ACON analysis Full CNSP analysis Interactive comparison tool

Dig into the metrics

Aclarion ROE CNS Pharmaceuticals ROE Aclarion operating margin CNS Pharmaceuticals operating margin Aclarion revenue growth CNS Pharmaceuticals revenue growth Aclarion free cash flow CNS Pharmaceuticals free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.